文献速递淋巴瘤造血干细胞移植与细胞治疗

双特异性LV20.19 CAR-T细胞治疗患者的长期结局及早期反应、晚期复发和生存的预测因素

Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells.
PubMed 文献 · Am J Hematol · 2022-09-20

该更新分析纳入LV20.19 CAR-T一期剂量递增和扩展试验中接受目标剂量2.5×10^6细胞/kg的16例患者,中位随访31个月,2年无进展生存率和总生存率分别为44%和69%,CAR-naïve大B细胞淋巴瘤患者(n=8)分别为50%和75%。体内扩增较低与晚期复发强相关,高代谢肿瘤体积和低效应:靶比阻碍早期治疗反应,桥接治疗和CAR-T输注日较高绝对淋巴细胞计数与较差生存结局相关。

要点

  • 中位随访31个月,2年PFS和OS分别为44%和69%,中位PFS为15.6个月,中位OS未达到。
  • CAR-naïve大B细胞淋巴瘤患者(n=8)2年PFS和OS分别为50%和75%。
  • 体内扩增较低与晚期复发强相关,高代谢肿瘤体积和低效应:靶比阻碍早期治疗反应。

核心结论

  • LV20.19 CAR-T的初始试验显示对复发/难治B细胞恶性肿瘤患者有有利长期结局的信号。

研究设计与样本

  • 此前报告的LV20.19 CAR-T一期剂量递增和扩展试验(NCT03019055)的更新分析,纳入接受目标剂量2.5×10^6细胞/kg的患者(n=16)。
  • 采用Kaplan-Meier法估计2年无进展生存率和总生存率,采用精确对数秩检验评估临床变量对生存结局的影响。

主要发现

  • 中位随访31个月(范围27-40),2年PFS和OS分别为44%和69%,中位PFS为15.6个月,中位OS未达到。
  • CAR-naïve大B细胞淋巴瘤患者(n=8)2年PFS和OS分别为50%和75%。
  • 无进展患者复发后活检未发现双靶抗原(CD19或CD20)丢失。
  • 体内扩增较低与晚期复发强相关,高代谢肿瘤体积和低效应:靶比阻碍早期治疗反应。
  • 桥接治疗和CAR-T输注日较高绝对淋巴细胞计数与较差生存结局相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We previously reported results of a first-in-human trial of bispecific LV20.19 chimeric antigen receptor T-cell (CAR-T) therapy, demonstrating high response rates in patients with relapsed, refractory (R/R) B-cell malignancies. We now report two-year survival outcomes and predictors of early response, late relapse, and survival. Patients from the previously reported phase 1 dose escalation and expansion trial of LV20.19 CAR-T therapy (NCT03019055) treated at target dose of 2.5 × 106 cells/kg (n = 16) were included in this updated analysis. Two-year progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier method. The relationship of in-vivo CAR-T expansion, tumor burden, and effector: target ratio on early response (day 28) and late relapse (>180 days post-CAR-T) were assessed. Exact log-rank testing was performed to evaluate the impacts of clinical variables on survival outcomes. With a median of 31 months (range 27-40) of follow-up, two-year PFS and OS were 44% and 69%. Median PFS and OS were 15.6 months and not reached, respectively. For CAR-naïve large B-cell lymphoma patients (n = 8), two-year PFS and OS were 50% and 75%. No patient with progression experienced dual target antigen (CD19 or CD20) loss on post-relapse biopsy. Lower in vivo expansion was strongly associated with late relapse. Early treatment response was impeded by high metabolic tumor volume and low effector: target ratio. Bridging therapy and higher absolute lymphocyte count on day of CAR-T infusion were associated with inferior survival outcomes. In conclusion, this initial trial of LV20.19 CAR-T demonstrates a signal for favorable long-term outcomes for patients with R/R B-cell malignancies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Zurko JC, Fenske TS, Johnson BD, et al. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022. PMID: 36068950. doi:10.1002/ajh.26718

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。